title: Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch.
abstract: Notch signaling is implicated in prostate cancer progression and docetaxel resistance. Cui and colleagues describe the additive efficacy and mechanisms of a γ-secretase inhibitor, PF-03084014, and docetaxel in preclinical models of prostate cancer, suggesting the need for further clinical development of Notch pathway modulators in men with metastatic prostate cancer.
authors: Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina.
authors: Tian
authors: T
authors: Zhang
authors: Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina. Division of Urology, Department of Surgery, Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina. andrew.armstrong@duke.edu.
authors: Andrew J
authors: AJ
authors: Armstrong
mesh_terms: D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors*; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*
chemical_list: D053829:Amyloid Precursor Protein Secretases